[Immunotherapy in multiple myeloma]

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Multiple myeloma patients with refractory disease or relapse after standard therapies (immunomodulators, proteasome inhibitors, CD38 antibodies) lack effective treatment options.
• The emergence of novel cell-based therapies is transforming the treatment landscape for relapsed or refractory multiple myeloma.

Purpose of the Study:

• To review the current clinical outcomes of T-lymphocyte redirecting therapies in relapsed or refractory multiple myeloma.
• To discuss the future challenges and toxicities associated with these advanced immunotherapies.

Main Methods:

• Review of published literature on bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies for multiple myeloma.
• Analysis of efficacy data and safety profiles of these novel treatment modalities.

Main Results:

• Bispecific antibodies and CAR T-cells demonstrate unprecedented antitumor activity in patients with refractory multiple myeloma.
• These novel agents are poised to become a cornerstone of future treatment strategies.

Conclusions:

• T-lymphocyte redirecting therapies represent a significant advancement for patients with relapsed or refractory multiple myeloma.
• Addressing specific toxicities and healthcare challenges associated with these therapies is crucial for successful implementation.